Last Updated: November 8, 2026

Details for Patent: RE46965

Name: Drug Patent Intelligence for US Patent RE46965
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which drugs does patent RE46965 protect, and when does it expire?

Patent RE46965 protects HALAVEN and is included in one NDA.

Protection for HALAVEN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-eight patent family members in fourteen countries.

Summary for Patent: RE46965

Title:	Intermediates for the preparation of analogs of Halichondrin B
Abstract:	The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4).
Inventor(s):	Brian Austad, Charles E. Chase, Francis G. Fang, Trevor Calkins, Bryan M. Lewis
Assignee:	Eisai R&D Management Co Ltd
Application Number:	US13/924,892
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE46965
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent RE46965

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: RE46965

PCT Information
PCT Filed	June 03, 2005	PCT Application Number:	PCT/US2005/019669
PCT Publication Date:	December 15, 2005	PCT Publication Number:	WO2005/118565

International Family Members for US Patent RE46965

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005250487	⤷ Start Trial
Canada	2567984	⤷ Start Trial
Canada	2822994	⤷ Start Trial
Canada	2935786	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.